These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 33200189)

  • 1. Prevention of CV outcomes in antihyperglycaemic drug-naïve patients with type 2 diabetes with, or at elevated risk of, ASCVD: to start or not to start with metformin.
    Sattar N; McGuire DK
    Eur Heart J; 2021 Jul; 42(26):2574-2576. PubMed ID: 33200189
    [No Abstract]   [Full Text] [Related]  

  • 2. Should Metformin Remain First-Line Medical Therapy for Patients with Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease? An Alternative Approach.
    Harrington JL; de Albuquerque Rocha N; Patel KV; Verma S; McGuire DK
    Curr Diab Rep; 2018 Jul; 18(9):64. PubMed ID: 30008022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of antihyperglycaemic therapies on proinsulin and relation between proinsulin and cardiovascular risk factors in type 2 diabetes.
    Hermann LS; Ranstam J; Vaaler S; Melander A
    Diabetes Obes Metab; 1999 Jul; 1(4):227-32. PubMed ID: 11228758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A proof of concept, preliminary study to determine the effect of Yogasnas in controlling type 2 diabetes mellitus in newly detected subjects (when compared to metformin monotherapy).
    Viswanathan V; Chacko PT; Lavanya M; Tilak P
    J Assoc Physicians India; 2006 Dec; 54():965-6. PubMed ID: 17334022
    [No Abstract]   [Full Text] [Related]  

  • 5. Patterns and determinants of new first-line antihyperglycaemic drug use in patients with type 2 diabetes mellitus.
    Geier AS; Wellmann I; Wellmann J; Kajüter H; Heidinger O; Hempel G; Hense HW
    Diabetes Res Clin Pract; 2014 Oct; 106(1):73-80. PubMed ID: 25139631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does background metformin therapy influence the cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes?
    Singh AK; Singh R
    Diabetes Res Clin Pract; 2021 Feb; 172():108536. PubMed ID: 33181201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is metformin cardioprotective?
    Sasali A; Leahy JL
    Diabetes Care; 2003 Jan; 26(1):243-4. PubMed ID: 12502689
    [No Abstract]   [Full Text] [Related]  

  • 8. [Metformin and kidneys].
    Smahelová A
    Vnitr Lek; 2008 May; 54(5):535-40. PubMed ID: 18630642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later.
    McGuire DK; Marx N; Johansen OE; Inzucchi SE; Rosenstock J; George JT
    Diabetes Obes Metab; 2019 May; 21(5):1073-1078. PubMed ID: 30690856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of type 2 diabetes: role of metformin.
    Charles MA; Eschwège E
    Drugs; 1999; 58 Suppl 1():71-3; discussion 75-82. PubMed ID: 10576529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From the World Congress of Cardiology, Barcelona, 2006--Support for wider metformin usage in type 2 diabetes.
    Cardiovasc J S Afr; 2006; 17(5):267. PubMed ID: 17117236
    [No Abstract]   [Full Text] [Related]  

  • 12. Metformin: diamonds are forever.
    Papanas N; Maltezos E; Mikhailidis DP
    Expert Opin Pharmacother; 2009 Oct; 10(15):2395-7. PubMed ID: 19678795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin and vascular protection: a diabetologist's view.
    Garber AJ
    Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S113-6. PubMed ID: 14502108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus.
    Dunn CJ; Peters DH
    Drugs; 1995 May; 49(5):721-49. PubMed ID: 7601013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cardiovascular effects of metformin: further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus.
    Anfossi G; Russo I; Bonomo K; Trovati M
    Curr Vasc Pharmacol; 2010 May; 8(3):327-37. PubMed ID: 19485923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line treatment for type 2 diabetes: is it too early to abandon metformin?
    Zaccardi F; Khunti K; Marx N; Davies MJ
    Lancet; 2020 Nov; 396(10264):1705-1707. PubMed ID: 33248483
    [No Abstract]   [Full Text] [Related]  

  • 17. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?
    Inzucchi SE; Fitchett D; Jurišić-Eržen D; Woo V; Hantel S; Janista C; Kaspers S; George JT; Zinman B;
    Diabetes Obes Metab; 2020 Apr; 22(4):631-639. PubMed ID: 31789445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of diabetes-associated secondary healthcare utilization between alternative oral antihyperglycaemic dual therapy combinations with metformin in patients with type 2 diabetes: an observational cohort study.
    Strongman H; D'Oca K; Langerman H; Das R
    Diabetes Obes Metab; 2015 Jun; 17(6):573-580. PubMed ID: 25735201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin: a multitasking medication.
    Bailey CJ
    Diab Vasc Dis Res; 2008 Sep; 5(3):156. PubMed ID: 18777487
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.